Iconic Stanley Hotel in Colorado purchased by public entity
The Stanley Hotel in Estes Park
CBS
That partnership is among the Colorado Educational and Cultural Facilities Authority, private bond investors, former owner John W. Cullen IV, and new manager Sage Hospitality Group. Cullen is at the helm of SPACE as chair and CEO.
"I have owned The Stanley for almost 30 years and can't imagine a better way to both preserve and grow it for generations to come," said Cullen in a statement.
According to CECFA, the nearly $400 million bond offering will also fund a major expansion of the two historic lodging buildings and a new 65,000 square foot event center. The event center will feature an 864-person auditorium and a horror film museum curated by Blumhouse Productions.
The Stanley Hotel
CBS
The hotel was initially built to attract wealthy vacationers from the East Coast to Colorado. However, the building was rocketed into fame after Stephen King visited decades ago. He reportedly was a guest during a slow season for the hotel. While staying at the hotel, King had a vision of writing a horror book that took place in the hotel, which became "The Shining" and was turned into a movie.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
10 minutes ago
- Associated Press
SRPT LEGAL ALERT: Lose Money on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law by August 25 Class Action Deadline (NASDAQ:SRPT)
NEW YORK, Aug. 03, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. (NASDAQ: SRPT) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Sarepta, you are encouraged to obtain additional information by visiting: Investors have until August 25, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Sarepta securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Dolgicer v. Sarepta Therapeutics, Inc., et al., No. 25-cv-05317. Why Was Sarepta Sued for Securities Fraud? Sarepta is a biopharmaceutical company focused on developing treatments for rare diseases. Sarepta's most important product is Elevidys, a therapy for the treatment of Duchenne muscular dystrophy. As alleged, Sarepta repeatedly touted the safety profile of Elevidys and told investors that the benefits of the treatment outweighed its risks. In truth, Elevidys causes fatal acute liver failure in some patients. The Stock Declines as the Truth Is Revealed On March 18, 2025, Sarepta announced that a patient that had been treated with Elevidys died after suffering acute liver failure. On this news, the price of Sarepta stock fell $27.81 per share, or over 27%, from $101.35 per share on March 17, 2025, to $73.54 per share on March 18, 2025. Nevertheless, on the same day, Sarepta assured investors that 'the benefit-risk of ELEVIDYS remains positive.' Next, on June 15, 2025, Sarepta announced that a second patient treated with Elevidys had died from acute liver failure and that it was suspending certain shipments of Elevidys and paused dosing in an ongoing clinical trial of the treatment. On this news, the price of Sarepta stock fell $15.24 per share, or more than 42%, from $36.18 per share on June 13, 2025, to $20.94 per share on June 16, 2025. Finally, on July 17, 2025, Sarepta revealed that a third patient treated with one of Sarepta's investigational treatments related to Elevidys had died from acute liver failure in June 2025. On this news, the price of Sarepta stock fell more than 40% on July 18, 2025. Click here for more information: What Can You Do? If you invested in Sarepta you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: Ross Shikowitz [email protected] 212.789.3619 Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named 'Elite Trial Lawyers' by the National Law Journal, among the top '500 Leading Plaintiff Financial Lawyers' by Lawdragon, 'Titans of the Plaintiffs' Bar' by Law360 and 'SuperLawyers' by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.
Associated Press
10 minutes ago
- Associated Press
SJM LEGAL ALERT: Lose Money on Your The J.M. Smucker Co. Investment? Contact BFA Law about its Securities Fraud Investigation (NYSE:SJM)
NEW YORK, Aug. 03, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into The J.M. Smucker Company (NYSE: SJM) for potential violations of the federal securities laws. If you invested in J.M. Smucker, you are encouraged to obtain additional information by visiting: Why Is J.M. Smucker being Investigated? J.M. Smucker manufactures and markets branded food and beverage products. In November 2023, the company completed an acquisition of Hostess Brands, Inc., a manufacturer and marketer of sweet baked goods brands. The company stated that the Hostess acquisition was 'highly complementary' and that 'underlying trends in snacking and specifically sweet snacking still bode well for the category.' In truth, it appears the company's Sweet Baked Snacks segment, which includes Hostess, significantly deteriorated in the face of declining trends in sweet snacking. The Stock Declines as the Truth Is Revealed On June 10, 2025, J.M. Smucker reported its Q4 2025 financial results and announced that it recognized a $867 million impairment charge related to the goodwill of its Sweet Baked Snacks segment and a $113 million impairment charge related to the Hostess brand trademark driven by the 'continued underperformance of the Sweet Baked Snacks segment.' On this news, the price of J.M. Smucker stock fell $17.44 per share, or more than 18%, from $111.85 per share on June 9, 2025, to $94.41 per share on June 10, 2025. Click here for more information: What Can You Do? If you invested in J.M. Smucker you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact: Ross Shikowitz [email protected] 212.789.3619 Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named 'Elite Trial Lawyers' by the National Law Journal, among the top '500 Leading Plaintiff Financial Lawyers' by Lawdragon, 'Titans of the Plaintiffs' Bar' by Law360 and 'SuperLawyers' by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit Attorney advertising. Past results do not guarantee future outcomes.
Yahoo
11 minutes ago
- Yahoo
Elvis biographer sets record straight about Colonel Tom Parker in hefty tome
The popular perception of Colonel Tom Parker is that he chiseled Elvis Presley out of a lot of money, forced his participation in some really bad 1960s movies and ensured Presley's late-career servitude to Las Vegas with a gambling addiction to match the King's own drug habit. But this is not the story Peter Guralnick looks to tell in his mammoth new book, 'The Colonel and the King: Tom Parker, Elvis Presley, and the Partnership that Rocked the World.' The book is long on the 'Colonel,' a moniker Parker claimed as his first name after the governor of Louisiana gave him the honorary title in 1948, and short on the King, who, after all, has been the subject of countless previous volumes. Some of the best were actually written by Guralnick, including 'Last Train to Memphis' and 'Careless Whispers.' Few writers know more about early rock 'n' roll and roots music, or have such passion for the subject. If you haven't read Guralnick, you should make a point to. Does that mean you should read 'The Colonel and the King?' Only if you deeply seek a comprehensive study of Elvis' longtime manager, who, it must be said, led a fascinating life defined by self-mythology and willful deception. Guralnick knew Parker from 1988 until his death in 1997, and you get the feeling the author saw his subject also as a friend. The book isn't hagiography, because Guralnick does so much research and reporting for every book that he's incapable of writing a one-sided account of any subject. That said, 'The Colonel and the King' often reads like a Parker apologia, or at least a concentrated effort to set some records straight. For instance, there's Parker's oft-reported reluctance to let Elvis tour internationally near the end of his career, for the reason that Parker wasn't a U.S. citizen and therefore didn't have a passport. 'The subject of much uninformed speculation,' Guralnick writes, suggesting other reasons. 'How could Elvis go to Japan, with its strict drug laws, how could he pass through all the customs stations he would have to clear in Europe if it were not to be a single small-country tour, without his prescribed medications? And who was going to carry those medications for him?' Parker's background as a carnival worker is often used to deride him. How could a mere carny know about the music business, or qualify him to steward the king of rock 'n' roll? But the liveliest and most revealing parts of 'The Colonel and the King' actually come before the Colonel meets the King, as Guralnick paints a picture of a tireless hustler desperate to reinvent himself. Parker long claimed that he was born Thomas Andrew Parker in West Virginia. In fact, he was born Andreas Cornelis van Kuijk in Breda, Holland. As a boy, he went by 'Dries.' His father was a liveryman and retired soldier. When young Dries fell in with a family circus and taught his father's horses to do tricks, his dad roared that the kid 'was no son of his, that he would never amount to anything, and, after beating him to within an inch of his life, announced that he would be banned from having anything to do with the stables.' As a teen, Parker smuggled himself to the U.S., got sent back, then made the trek again, this time successfully. He developed a habit of being unofficially adopted by surrogate families and then disappearing without a trace, a pattern that continued when he joined the U.S. Army, went AWOL and eventually received an honorable discharge in 1933, with a certificate of disability that cited reasons of 'Psychic Psychogenic Depression' (Parker claimed he was discharged for having a bad leg). He eventually ended up in Florida, where he became a jack-of-all-trades carny and developed a sharp instinct for advance publicity and promotion. Read more: Looking back at the 1968 TV special that made Elvis Presley matter again Elvis wasn't Parker's first music client; he developed his chops first with early pop superstar Gene Austin, then country star Hank Snow. But when Parker first witnessed Elvis and Elvis mania at the Louisiana Hayride in 1955, he was determined to manage him. Then it was on to selling him, cunningly and ferociously, to RCA, 20th Century Fox and whoever else would help build the mighty Elvis industry. 'The Colonel and the King' is a hunk of a book, weighing in at 624 pages. That includes about 250 pages of annotated letters to and from the Colonel, which might have been better used, in truncated form, spread throughout the narrative proper. You also get the sense that perhaps the author was rather quick to take Parker for his word, considering Parker himself once joked that he was writing an autobiography called 'The Benevolent Con Man.' One can admire Guralnick's thoroughness and sense of mission while also wishing for tighter results. I found the arc of Parker's story quite intriguing, even as I got a little tired of it. Vognar is a freelance culture writer. Get the latest book news, events and more in your inbox every Saturday. This story originally appeared in Los Angeles Times. Solve the daily Crossword
